Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
WidePoint Corporation reported financial results for the third quarter ended September 30, 2026, and provided an update on its DHS CWMS 3.0 contract status. Despite a GAO protest setback, the company was awarded 40 new and replacement task orders valued at $33.7 million during the quarter under existing bridge contracts.
Term
Q3 2026
“I want to acknowledge that the last few months have presented challenges and outcomes that fell short of what we had envisioned for our DHS program. As you know, the Government Accountability Office, or the GAO's decision to sustain the protest filed regarding the pending CWMS 3.0 award, while not unprecedented, was still an unexpected setback.”
Jin Kang, Chief Executive Officer, President and Director
“While delays and setbacks are frustrating, we are well-positioned to withstand near-term headwinds as we await a decision from DHS.”
Jin Kang, Chief Executive Officer, President and Director
ALX Oncology reported a net loss of $57.7 million for the nine months ended September 30, 2026, an improvement from the $78.8 million loss in the prior year period. The company significantly strengthened its balance sheet through equity offerings, increasing total stockholders' equity to $125.9 million from $26.0 million at the end of 2025.
US Alliance Corp reported a net loss of $820,543 for the nine months ended September 30, 2026, compared to a loss of $795,892 in the prior year period. Total assets remained stable at $149.4 million, while the company saw a significant shift in its investment portfolio toward mortgage loans and a decrease in cash and cash equivalents.
Neumora Therapeutics reported a net loss of $34.4 million for the third quarter of 2026, an improvement from the $56.8 million loss in the prior year period. The company's cash and cash equivalents decreased significantly to $85.7 million as of September 30, 2026, compared to $182.5 million at the end of 2025, while total stockholders' equity fell to $18.6 million.
Virtuix Holdings reported Q2 fiscal 2027 financial results featuring 55% sequential revenue growth to $1.2 million, driven by a 105% increase in Omni One revenue following its launch for Meta Quest. The company also announced a non-binding letter of intent to acquire defense technology firm STS International for approximately $12 million to expand its presence in the government and defense sectors.
Tancheng Group Co., Ltd. reported zero revenue for the nine months ended September 30, 2026, as it pivoted from product sales to the development of a cultural tourism project. The company recorded a net loss of $338,896 for the period and maintains a significant accumulated deficit of $2.4 million, raising concerns about its ability to continue as a going concern.
Dawson Geophysical reported third quarter 2026 financial results, including fee revenue of $10.8 million and a net loss of $5.2 million. The company noted that two large channel crew jobs were delayed from Q3 into Q4 due to government permitting issues, but highlighted a strengthened backlog and renewed demand for seismic data acquisition in North America.
“Although our financial performance fell short of our expectations in the third quarter, I cannot be more excited about how this Company is positioned to capitalize on the renewed demand for seismic data acquisition services in North America. We are observing increased demand in Canada and in the United States across the oil and gas space and in other non-traditional markets, such as Carbon Capture, Utilization, and Storage (“CCUS”) and geothermal, and we are scheduled to start our first geothermal data acquisition in November.”
Tony Clark, Dawson’s President and CEO
“I evaluate the Company’s performance over the long term rather than quarterly, and 2026 will be the third year in a row of increasing top-line revenue, improved gross margins and higher Adjusted EBITDA, and I expect that to continue in 2027.”
Idaho Strategic Resources reported a significant increase in nine-month revenue to $37.1 million in 2026, up from $27.8 million in 2025, driven by product sales. Net income attributable to the company rose to $12.7 million for the nine-month period, while the company transitioned its investment strategy by transferring $64.2 million of US treasury notes from held-to-maturity to available-for-sale.
Veritone reported Q3 2026 revenue of $18.6 million, a 30% year-over-year decrease, and a net loss of $19.2 million. Alongside results, the company announced a debt exchange for $38.7 million of convertible notes and a $40 million senior secured term loan commitment from Blue Torch Capital to improve its liquidity position.
Term
Q3 2026
“We have spent the majority of fiscal 2026 taking actions to put Veritone in a stronger financial and operational position. With our newly announced convertible notes exchange and commitment letter, combined with our recent cost reduction efforts, we are on a clear path to greatly improve our financial position and ability to execute our operating model and product strategy.”
Ryan Steelberg, President and Chief Executive Officer of Veritone
ALX Oncology reported third quarter 2026 financial results, ending the period with $147.2 million in cash and investments, which is expected to fund operations through the first half of 2028. The company highlighted clinical progress for evorpacept and ALX2004, with topline data from the ASPEN-09-Breast trial now expected in the second half of 2027.
“Throughout the third quarter, we continued to make significant progress across both the ASPEN-09-Breast and ALX2004 clinical trials. The recent publication of ASPEN-06 results in Nature Medicine further reinforces the promise of evorpacept and our biomarker-driven development strategy.”
Jason Lettmann, Chief Executive Officer of ALX Oncology
Apnimed, Inc. is a late-stage clinical pharmaceutical company focused on its lead product candidate, Oxnimbi, which has completed Phase 3 clinical trials. The company reports significant operating losses since inception and anticipates requiring substantial additional funding to support its commercialization efforts and regulatory approval processes.
Iambic Therapeutics reported third quarter 2026 financial results, highlighting a pro-forma cash position of $455 million following its IPO and upfront payments from AbbVie. The company reported year-to-date collaboration revenue of approximately $24 million and total operating expenses of $108 million. Key operational milestones included the launch of its Enchant v3 AI model and positive Phase 1/2 data for its HER2 inhibitor, IAM1363.
Term
Q3 2026
“Iambic’s mission is to make better technology for better medicines, and we believe that the past several months showed that at work across every part of our business. At ESMO, our updated clinical data showed the intracranial activity and tolerability for IAM1363, and we are preparing to start a registrational trial in 2027, subject to regulatory approval. We submitted the IND and have received a Safe-to-Proceed Letter for a Phase 1/2 trial for IAM217, our second wholly owned and platform-discovered candidate, with an anticipated IND submission for IAM-C1, our CDK2/4 inhibitor, close behind. We launched Enchant v3, a huge advance in the core AI technology that underpins our molecular superintelligence platform, and AbbVie and Bayer each chose to bring our platform to bear on their own discovery work through new Iambic partnerships. Our IPO gives us the resources to advance our pipeline through major inflection points and to keep scaling the platform behind it.”
International Battery Metals Ltd. reported a net income of $2.14 million for the six months ended September 30, 2026, primarily driven by a $7.93 million non-cash gain from the change in fair value of warrant liabilities. Despite the net profit, the company experienced an operating loss of $5.78 million and negative cash flow from operations as it continues to market its modular direct lithium extraction (MDLE) technology.
Jasper Therapeutics reported a significant net loss of $148.4 million for the nine months ended September 30, 2026, primarily driven by a $129.5 million charge for acquired in-process research and development. Despite the loss, the company strengthened its liquidity through a financing and acquisition, ending the period with $135.3 million in cash and cash equivalents.
International Battery Metals reported Q2 fiscal 2027 results, including a net income of $2.2 million driven by a $5.0 million gain in the fair value of warrant liabilities. The company announced plans to build a compact, transportable pilot plant to provide field data for North American resource owners and expects to secure a $12.0 million bridge loan from its largest investor.
Term
Q2 2027
“We continue to evaluate opportunities across North America, including through an active laboratory testing program. Our ongoing discussions with North American resource owners have made clear that one of their biggest challenges is they need field data from their own resources before making investment decisions. To meet that need, we have begun engineering a compact pilot plant that can be deployed at sites quickly, and at a lower cost than our existing demonstration plant.”
Adagio Medical Holdings, Inc. reported a significant decrease in cash and cash equivalents from $17.1 million at the end of 2025 to $3.1 million as of September 30, 2026. The company highlighted substantial risks regarding its ability to continue as a going concern and is exploring strategic alternatives to maximize stockholder value.
Apnimed reported third quarter 2026 financial results, highlighting a cash position of $351.8 million following its upsized IPO in August. The company's NDA for AD109 (Oxnimbi) for the treatment of obstructive sleep apnea remains under FDA review with a PDUFA goal date of February 28, 2027.
“We are in a transformational period at Apnimed. With our NDA for AD109 (proposed proprietary name Oxnimbi) under FDA review and a PDUFA goal date of February 28, 2027, we are advancing our launch readiness while continuing to strengthen the clinical story.”
Accelevation Holdings Corp. reported Q3 2026 financial results with revenue growing 66% year-over-year to $202.2 million and a significant bookings increase of 364%. The company also issued an amendment to correct errors in its original earnings release regarding SG&A margins and Adjusted SG&A calculations.
“At Accelevation, we design, manufacture, and install mission-critical infrastructure for customers who rely on our speed and certainty of delivery, and our third quarter results reflect the strength of our operating model and underlying markets.”
Michael Rubiera, Co-Founder and Chief Executive Officer
“We delivered strong growth, profitability, and cash generation in the quarter. Revenue increased more than 60%, bookings grew more than 350%, backlog rose to approximately $1.7 billion, and Adjusted EBITDA margins approached 19% following a weaker first half of the year.”
Adagio Medical reported Q3 2026 financial results, highlighting a net income of $17.8 million primarily driven by a $23.0 million gain from the change in fair value of warrant liabilities. The company also announced that its Board of Directors has initiated a formal process to explore strategic alternatives to maximize shareholder value while continuing clinical progress on its vCLAS Ultra System.
Term
Q3 2026
“The third quarter was defined by progress in the clinical and regulatory programs that we believe are the foundation for the value of Adagio and our ULTA platform. Our PMA application for the vCLAS Ventricular Ablation System remains under FDA review, and we initiated the vCLAS Ultra IDE study, which builds on the FULCRUM-VT results with a faster, more maneuverable next-generation catheter.”
Todd Usen, Chief Executive Officer of Adagio Medical
“As the Board’s review of strategic alternatives continues, we have aligned our cost structure around these prioritized programs and remain focused on maximizing value for our shareholders.”
Todd Usen, Chief Executive Officer of Adagio Medical
Suncrete, Inc. reported a significant revenue increase to $300.0 million for the nine months ended September 30, 2026, compared to $130.8 million in the prior year, driven by acquisition activity. However, the company realized a net loss attributable to common stockholders of $55.0 million for the period, primarily due to higher interest expenses and substantial acquisition-related costs.
Montauk Renewables reported total operating revenues of $150.6 million for the nine months ended September 30, 2026, up from $133.0 million in the prior year. The company achieved a net income of $2.37 million for the period, recovering from a net loss of $0.75 million in 2025, despite an operating loss of $2.6 million driven by higher operating and maintenance expenses.
Nuvera Communications reported total operating revenues of $17.4 million for the third quarter of 2026, a slight decrease from $18.0 million in the prior year, primarily due to lower A-CAM/FUSF and video service revenues. Despite the revenue dip, operating income improved to $2.66 million as the company reduced operating expenses, though it ultimately recorded a net loss of $176,261 for the quarter due to high interest expenses.
TerraVolt Holdings, Inc. reported a net loss of $3.9 million for the nine months ended September 30, 2026, compared to a $5.7 million loss in the prior year period. The company is currently pre-revenue and focused on financing and constructing proposed data center operations, with total assets increasing to $13.55 million primarily due to new restricted cash and other assets.
Jasper Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided a corporate update following its acquisition of Kira Pharmaceuticals. The company highlighted progress in its Phase 2 renal basket study for vensobafusp alfa (KP104), including completed enrollment in the IgA nephropathy cohort and the dosing of the first patient with IC-MPGN.
“We have made progress advancing our development programs in recent months following our acquisition of Kira Pharmaceuticals, highlighted by the recent completion of enrollment in the first cohort of our Phase 2 renal basket study evaluating vensobafusp alfa (KP104) in patients with IgA nephropathy (IgAN).”
Jeet Mahal, President and Chief Executive Officer of Jasper
“We believe that the bifunctional ability of vensobafusp alfa to inhibit both the alternative and terminal complement pathways may provide the potential for differentiated onset and efficacy in complement driven diseases, and we look forward to presenting interim data from the IgAN cohort in the fourth quarter of 2026 and additional updates from our pipeline programs in 2027.”
Jeet Mahal, President and Chief Executive Officer of Jasper
Venu Holding Corp reported its Q3 2026 financial results, highlighting a 59% increase in total assets to $587.6 million since year-end 2025. The company is transitioning from a construction phase to an operational phase with the upcoming opening of the Regent Bank Amphitheater on New Year's Eve and the Sunset Amphitheater McKinney in Q1 2027.
Term
Q3 2026
“Next quarter, VENU moves from building to operating. With two venues coming online, we expect to see a meaningful step up in ticketing, food and beverage, and sponsorship revenue in fiscal 2027. Content drives all of it, and we already have more than 110 holds on the calendar across our portfolio.”
J.W. Roth, Founder, Chairman, and Chief Executive Officer
“What you see in our results today is the cost of bringing more than $600 million in assets online by mid-2027, and we continue to expect to be in a position to provide financial guidance in the middle of next year.”
J.W. Roth, Founder, Chairman, and Chief Executive Officer
Outdoor Holding Company reported its fiscal second quarter 2027 results, featuring a 14.6% revenue increase to $13.7 million and net income growth to $2.3 million. The company outperformed the broader firearms market with a 10.3% increase in Gross Merchandise Value (GMV) and a 25 basis point increase in take rate to 6.59%.
LanzaTech Global, Inc. reported total revenues of $30.5 million for the nine months ended September 30, 2026, compared to $27.8 million in the prior year period. The company significantly reduced its research and development expenses from $41.7 million to $10.8 million year-over-year, contributing to a narrowed accumulated deficit. However, the filing includes a cautionary note regarding the company's ability to continue as a going concern and its need for additional financing.
Galectin Therapeutics reported financial results for the quarter ended September 30, 2026, and provided a business update on its Phase 3 clinical trial protocol for belapectin in MASH cirrhosis. The company reached alignment with the FDA on the Phase 3 trial design and presented positive new analyses from its NAVIGATE trial at the AASLD Annual Meeting.
Term
3 months
“New analyses were presented at AASLD, marking the fourth consecutive major liver conference where Galectin data was included in an oral presentation. We were extremely pleased by the positive feedback received on the oral presentation as well as the two poster presentations and are excited that our data was included in the AASLD conference highlights and the portal hypertension debrief.”
Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics
“As previously disclosed, we submitted our registrational Phase 3 protocol to FDA in the third quarter after reaching alignment on primary elements of the planned Phase 3 trial design. Additional information is expected to be presented at the Annual Stockholders’ Meeting on December 3, 2026.”
Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics
LanzaTech Global reported Q3 2026 revenue of $9.5 million and a net loss of $178.0 million, which was primarily driven by a $166.4 million non-cash unrealized fair value loss on its investment in SGLT. The company highlighted significant cost reductions, with operating expenses down 35% year-over-year, and achieved the world's first ISCC EU certification for recycled carbon fuels from steel mill waste gases.
Term
Q3 2026
“Our third quarter results show continued improvement in our financial and operating performance, building on the progress we have made throughout 2026. The actions we took to reshape LanzaTech are now showing up in our results quarter after quarter; we have held quarterly operating expenses steady for multiple quarters, which tells us the lower cost base we built is durable and sustainable. Our cost structure is now reset for where we are headed operationally and strategically, and LanzaTech now has a much improved position upon which to advance its platform toward commercialization and long-term profitability.”
Dr. Jennifer Holmgren, CEO of LanzaTech
“We are building a business that can monetize waste carbon across multiple end markets rather than depend on a single route to market. This quarter, Hebei Shoulang, a commercial facility using LanzaTech technology, achieved the world’s first ISCC EU Recycled Carbon Fuel certification for ethanol made from steel mill waste gases. This creates a near-term pathway into European road and marine fuel markets, and we have begun commercial discussions with major energy and chemicals companies to convert certification into revenue.”
Galectin Therapeutics reported a net loss of $17.7 million for the nine months ended September 30, 2026, an improvement from the $25.3 million loss in the prior year period. A significant balance sheet event occurred with the conversion of $105.2 million in debt into common stock, substantially reducing total liabilities and increasing the common shares outstanding to over 100 million.